IVERIC bio, Inc. (NASDAQ:ISEE) management will conduct a conference call for 2nd November 2020 at 8:00 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website ivericbio.com
Earnings Expectation
IVERIC bio, Inc. is expected to report third quarter earnings results, before market open, on Monday 2nd November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.22 per share. Looking ahead, the full year loss are expected at $ 0.92 per share.
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy.
